Intercell AG, the Austrian vaccine company, has obtained €25 million in debt and equity financing from BB Biotech AG, a Swiss investor in biotech companies. The financing is being made through a wholly-owned BB Biotech AG subsidiary. ---Subscribe to MedNous to access this article--- Company News Finance, Grants, Deals
